The present study aimed to directly compare the efficacy and safety of azacitidine and decitabine in patients with myelodysplastic syndromes (MDS). We compared the overall response rate (ORR) (complete responses, partial responses, marrow complete responses, and haematological improvements), overall survival (OS), event-free survival (EFS), time to leukaemic transformation, and adverse outcomes between azacitidine and decitabine. To minimize the effects of treatment selection bias in this observational study, adjustments were made using the propensity-score matching method. Among 300 patients, 203 were treated with azacitidine and 97 with decitabine. Propensity-score matching yielded 97 patient pairs. In the propensity-matched cohort, there...
ObjectiveAzacitidine is the standard of care for higher-risk myelodysplastic syndromes (MDS). We eva...
International audienceMyelodysplastic syndromes (MDS) are a group of common bone marrow disorders ch...
Azacitidine (AZA) has proven effective in Myelodysplastic Syndromes (MDS), and the currently approve...
Abstract Background Hypomethylating agents (HMA), azacitidine, and decitabine are frequently used in...
Background: The hypomethylating agents (HMAs) azacitidine (AZA) and decitabine (DAC) have been widel...
BACKGROUND: Azacitidine induces responses and prolongs overall survival compared with conventional c...
The hypomethylating agents, decitabine (DEC) and azacitidine (AZA), allowed more elderly acute myelo...
This study was performed to identify whether cytogenetics, International Prognostic Scoring System (...
Objective: To investigate the efficacy and safety of decitabine combined with half the amount of CAG...
Jacqueline S Garcia1, Nitin Jain1, Lucy A Godley1,21Section of Hematology/Oncology, Department of Me...
Hypomethylating agents have recently been shown to improve the outcome of patients with myelodysplas...
BACKGROUND: Azacitidine induces responses and prolongs overall survival compared with conventional c...
BACKGROUND: Azacitidine induces responses and prolongs overall survival compared with conventional c...
BACKGROUND: Drug treatments for patients with high-risk myelodysplastic syndromes provide no surviva...
We compared the efficacy of azacitidine (AZA) and decitabine (DEC) in elderly patients with untreate...
ObjectiveAzacitidine is the standard of care for higher-risk myelodysplastic syndromes (MDS). We eva...
International audienceMyelodysplastic syndromes (MDS) are a group of common bone marrow disorders ch...
Azacitidine (AZA) has proven effective in Myelodysplastic Syndromes (MDS), and the currently approve...
Abstract Background Hypomethylating agents (HMA), azacitidine, and decitabine are frequently used in...
Background: The hypomethylating agents (HMAs) azacitidine (AZA) and decitabine (DAC) have been widel...
BACKGROUND: Azacitidine induces responses and prolongs overall survival compared with conventional c...
The hypomethylating agents, decitabine (DEC) and azacitidine (AZA), allowed more elderly acute myelo...
This study was performed to identify whether cytogenetics, International Prognostic Scoring System (...
Objective: To investigate the efficacy and safety of decitabine combined with half the amount of CAG...
Jacqueline S Garcia1, Nitin Jain1, Lucy A Godley1,21Section of Hematology/Oncology, Department of Me...
Hypomethylating agents have recently been shown to improve the outcome of patients with myelodysplas...
BACKGROUND: Azacitidine induces responses and prolongs overall survival compared with conventional c...
BACKGROUND: Azacitidine induces responses and prolongs overall survival compared with conventional c...
BACKGROUND: Drug treatments for patients with high-risk myelodysplastic syndromes provide no surviva...
We compared the efficacy of azacitidine (AZA) and decitabine (DEC) in elderly patients with untreate...
ObjectiveAzacitidine is the standard of care for higher-risk myelodysplastic syndromes (MDS). We eva...
International audienceMyelodysplastic syndromes (MDS) are a group of common bone marrow disorders ch...
Azacitidine (AZA) has proven effective in Myelodysplastic Syndromes (MDS), and the currently approve...